Kriya acquires Redpin Therapeutics

Marking a second M&A deal this year, USA-based gene therapy company Kriya Therapeutics today announced the acquisition of a privately held biotechnology company Redpin Therapeutics, which is developing regulatable gene therapies for intractable diseases of the nervous system.

The acquisition, financial terms of which are not disclosed, serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).

Kriya noted that Redpin’s proprietary chemogenetics platform can selectively activate or silence disease-causing neurons, while leaving normal functioning cells unaffected. Currently available treatments for neurological disorders typically rely on systemically administered drugs or surgical interventions to address local neuron dysfunction. However, these approaches can have limited efficacy and off-target side effects. In contrast, chemogenetics leverages gene products that are selectively responsive to a chosen small molecule.